Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

08/11/2021 | 04:09pm EDT

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2021, C4 Therapeutics, Inc. (the "Company") issued a press release announcing its financial results and business highlights for the quarter ended June 30, 2021. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On August 11, 2021, the Company issued a press release entitled "C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma."

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.



                Exhibit
                Number                  Description
                99.1        Press release issued August 11, 2021
                99.2        Press release issued August 11, 2021








--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about C4 THERAPEUTICS, INC.
10/14C4 THERAPEUTICS : SVB Leerink Starts C4 Therapeutics at Outperform with $67 Price Target
MT
10/05INSIDER SELL : C4 Therapeutics
MT
09/30C4 THERAPEUTICS : Stifel Starts C4 Therapeutics at Hold With $45 Price Target
MT
09/24INSIDER SELL : C4 Therapeutics
MT
09/22INSIDER SELL : C4 Therapeutics
MT
09/17INSIDER SELL : C4 Therapeutics
MT
09/15Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending..
CI
09/15Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Endin..
CI
09/14INSIDER SELL : C4 Therapeutics
MT
08/12C4 THERAPEUTICS' : Q2 Loss Narrows, Revenue Grows; Secures Orphan Drug Designation for Mul..
MT
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations